![Azeza Fdel PhD (Cardiff)](https://profiles-cardiff.imgix.net/attachments/9021?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Azeza Fdel
(she/her)
PhD (Cardiff)
Teams and roles for Azeza Fdel
Research student
Research Assistant
School of Biosciences
Overview
I am a biomedical researcher with a strong background in molecular and cancer biology. I completed my PhD at Cardiff University, where my research focused on understanding the role of OSR1 kinase signalling in triple negative breast cancer, with the aim of identifying novel therapeutic strategies. My work involved advanced biochemical and cell-based approaches to investigate key signalling pathways that drive tumour progression.
I am currently working as a Research Assistant at the Medicines Discovery Institute (MDI), Cardiff University, contributing to neuroscience drug discovery and translational research.
My research interests lie at the intersection of cell signalling, cancer biology, and therapeutic development, and I am passionate about translating fundamental science discoveries into meaningful clinical applications.
Publication
2025
- Fdel, A. M. et al. 2025. Oxidative stress-responsive 1 kinase catalytic activity promotes triple negative breast cancer oncogenic potential. ACS pharmacology & translational science (10.1021/acsptsci.4c00603)
2023
- Lambourne, O. A. et al. 2023. PINK1-Dependent mitophagy inhibits elevated ubiquitin phosphorylation caused by mitochondrial damage. Journal of Medicinal Chemistry 66(11), pp. 7645-7656. (10.1021/acs.jmedchem.3c00555)
Articles
- Fdel, A. M. et al. 2025. Oxidative stress-responsive 1 kinase catalytic activity promotes triple negative breast cancer oncogenic potential. ACS pharmacology & translational science (10.1021/acsptsci.4c00603)
- Lambourne, O. A. et al. 2023. PINK1-Dependent mitophagy inhibits elevated ubiquitin phosphorylation caused by mitochondrial damage. Journal of Medicinal Chemistry 66(11), pp. 7645-7656. (10.1021/acs.jmedchem.3c00555)